Antibody Drug Conjugate Market Focuses on SWOT analysis, Synopsis, Development Plans 2022 to 2030

 

Antibody Drug Conjugate Market Analysis

The global antibody drug conjugate (ADC) market is projected to witness a stupendous growth at a notable 16.70% CAGR over the predicted years. ADCs are made of three parts- first a specific antibody for binding, an antigen that has limited expression on the normal cells, second a cytotoxic agent to kill target cancer cells and third a chemical linker to attach the cytotoxic agent to the antibody. This is how antibody drug conjugates work. They are the new age of therapeutic agents. One of the key advantages of antibody drug conjugates is that this will help in bringing together the finest characteristics of both antibodies as well as the chemotherapy’s cytotoxic potential.

There are many factors that is fuelling the growth of the antibody drug conjugate market. The different market trends and factors in this market according to an analysis performed by Market Research Future (MRFR) include increasing prevalence of cancer, advancement in medical technology, increased investment in R & D, efficacy of ADC in treating diseases, rising collaboration amid biotechnology and biopharmaceuticals and research institutes, preclinical research, growing geriatric population and rise in obese population. On the contrary, the soaring cost related to the procedure may hamper the growth of the antibody drug conjugate market.

Regional Analysis

Based on region, the antibody drug conjugate market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America is expected to accrue maximum share in the market due to advancement in manufacturing techniques, technological innovation and contribution of nanotechnology to create ADC. The U.S. FDA has given approval to only three ADC. The antibody drug conjugate market in Europe will have the second largest share followed by the APAC region. APAC is an emerging market and the factors that are driving the growth of the market include increasing government initiatives. A good number of products are under the pipeline and such developments are performed under license agreements.

Market Segmentation

As per MRFR report, the global antibody drug conjugate market is segmented on the basis of type, product, technology, application and end-user.

Based on type, it is segmented into drug/toxin, linker, monoclonal antibodies and others. Of these, the antibody drug conjugate linker is expected to have the maximum share in the antibody drug conjugate market.

Based on application, the antibody drug conjugate market is segmented into lymphoma, multiple myeloma, solid tumors, skin cancer, breast cancer, colon cancer, lung cancer, glioblastoma, ovary cancer, pancreas cancer, kidney cancer, prostate cancer and leukemia. Leukemia is further segmented into Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Acute Myeloid Leukemia (AML). Of these, breast cancer had the maximum share owing to its increasing prevalence.

Based on product, it is segmented into Kadcyla, Adcertis and others.

Based on technology, the antibody drug conjugate market is segmented into Immunomedics technology, Seattle Genetics technology, ImmunoGen technology and others.

Based on end-user, it is segmented into biopharmaceutical companies, biotechnology companies, academic research institutes, specialized cancer and others.

Key Players

The antibody drug conjugate market players include Synthon (U.S.), Mersana Therapeutics (U.S.), Oxford BioTherapeutics (U.S.), Heidelberg Pharma (Germany), Progenics Pharmaceuticals (U.S.), Astellas Pharma/Agensys (Japan), Bayer HealthCare (Germany), Agensys, Inc. (U.S.), Concortis Biotherapeutics (U.S.), Genentech (U.S.), AbbVie Inc. (U.S.), Millennium Pharmaceuticals (U.S.), Celldex Therapeutics (U.S.), Pfizer Inc. (U.S.), Immunomedics (U.S.), Antikor (U.K.), Roche Holding AG (Switzerland), ImmunoGen, Inc. (U.S.), and Seattle Genetics (U.S.).

Feb 2019- The Food and Drug Administration (FDA) has granted priority review to ADC (antibody drug conjugate) for diffusing large B-Cell Lymphoma. The chief medical officer of global product development is working with the Food and Drug Administration for bringing this vital novel option to patients having this aggressive ailment as fast as possible. The FDA is most likely to come up with the decision by August 19, 2019.

Jan 2019- Daiichi Sankyo has come up with a late-stage study of ADC to treat patients having low expressing HER2 metastatic/unresectable breast cancer.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Cardiac Monitoring and Cardiac Rhythm Management Market Share, Trends, Leading Players, Business Overview, Sales Statistics and Outlook by 2030

  Cardiac Monitoring and Cardiac Rhythm Management Devices Market Highlights The increasing demand for minimally invasive surgeries drives the growth of this market. Advanced technologies in cardiac monitoring and cardiac rhythm management devices have also led to growth in this market.  However, factors such as stringent regulatory approval procedures, the high cost of cardiac devices, and lack of reimbursement policies in developing countries are hindering the growth of the market. Rising prevalence of cardiovascular diseases and the increasing number of unmet medical needs in undeveloped countries are leading to the growth of the cardiac monitoring and cardiac rhythm management device market . Technical advancements in drug-eluting, MRI compatible pacemakers, and Holter monitors are some of the factors leading to the growth of this market. The growth of the global cardiac monitoring device market is driven by the high prevalence of cardiovascular disorders worldwide. Cardiac m
Read more

Africa Medical Devices Market | Analysis, Size, Growth, Key Players, Segmentation and Forecast By 2030

  Africa Medical Devices Market – Overview The Africa Medical Devices market is growing with a steady pace; mainly due to the rapidly growing middle-income group, increasing healthcare expenditure, increasing number of medical tourists, proliferation of hospitals, government programs and support, and increasing incidence of lifestyle diseases. Moreover, rising economic growth also drive the market in this region. According to the World Bank Group, in 2016, GDP of the Middle East & North Africa experienced the growth in GDP by 4.89%. It is expected that Africa’s macroeconomic climate over the next decade will expand the health care gap, as higher incomes will create new demand for the medical devices market. The Africa medical devices market to reach around $ 7069.61 million from $ 7.19 billion in 2030, by the end of the forecast period at a CAGR of 7.10 %. Companies are continuously engaged in merger and acquisition activities for the development of the best medicine to cure
Read more

Clinical Laboratory Test Market Dynamics, Future Insights, Share Value, Growth Outlook, COVID-19 Impact and Size Projection By 2030

  Clinical Laboratory Test Market Highlight The Clinical Laboratory Test market is growing mainly due to growing awareness and rising adoption of anti-inflammatory drugs. According to a recent study report published by the Market Research Future, the Clinical Laboratory Test market is booming and expected to gain prominence over the forecast period. The clinical laboratory test market size was valued USD 189 Billion in 2021 and expected to reach USD 325 billion by 2030 at 6.9% CAGR during the forecast period 2022-2030. Clinical laboratory test market has emerged as the most growing segment of healthcare over the past few years. Clinical laboratory testing includes all routine check-ups and other pathology tests for the diagnosis of various diseases ranging from CBC and other routine blood test, anatomical pathological testing, molecular, immunological, drug testing and other tests for disease diagnosis and treatment. CBC and other routine blood tests are the most common type of te
Read more